ARCA biopharma, Inc. (ABIO)
NasdaqCM - NasdaqCM 延遲價格。貨幣為 USD。
加入追蹤清單
收市：04:00PM EDT
收市後：
| 前收市價 | 3.7200 |
| 開市 | 3.7500 |
| 買盤 | 3.9700 x 200 |
| 賣出價 | 4.0300 x 100 |
| 今日波幅 | 3.7500 - 4.0000 |
| 52 週波幅 | 1.5600 - 4.0000 |
| 成交量 | |
| 平均成交量 | 1,463,624 |
| 市值 | 58.028M |
| Beta 值 (5 年，每月) | 0.88 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.4200 |
| 業績公佈日 | 2024年7月19日 - 2024年7月23日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
BenzingaSmall-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details
ARCA Biopharma Inc (NASDAQ:ABIO) and Oruka Therapeutics have entered into a definitive agreement to combine the companies in an all-stock transaction. Oruka Therapeutics is a privately held biotechnology company developing novel biologics for chronic skin diseases, including plaque psoriasis. The resulting entity will focus on advancing Oruka’s pipeline, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to o
